R. Axelrod
About
R. Axelrod is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology.
According to data from OpenAlex, R. Axelrod has authored 38 papers receiving a total of 399 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Otorhinolaryngology. Recurrent topics in R. Axelrod's work include Head and Neck Cancer Studies (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). R. Axelrod is often cited by papers focused on Head and Neck Cancer Studies (14 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Lung Cancer Research Studies (9 papers). R. Axelrod collaborates with scholars based in United States, Canada and Netherlands. R. Axelrod's co-authors include Randal S. Weber, David I. Rosenthal, K. Kian Ang, Athanassios Argiris, Craig Silverman, M. A. List, Barbara Burtness, Arlene A. Forastiere, Adam S. Garden and Jonathan J. Beitler and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.
In The Last Decade
R. Axelrod
38 papers receiving 389 citations
Peers
R. Axelrod
Lora S. Wang United States
Tsien Fua Australia
Sophia Hsu United States
Manuel Molina United States
Alistair Robertson United Kingdom
Virginia Osborn United States
Gopal Bajaj United States
Everett E. Vokes United States
Bhavana V. Chapman United States
Ashwini Budrukkar India
Citations per year, relative to R. Axelrod R. Axelrod (= 1×)
peers
Lora S. Wang
Countries citing papers authored by R. Axelrod
Since
Specialization
Citations
This map shows the geographic impact of R. Axelrod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Axelrod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Axelrod more than expected).
Fields of papers citing papers by R. Axelrod
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by R. Axelrod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Axelrod. The network helps show where R. Axelrod may publish in the future.
Co-authorship network of co-authors of R. Axelrod
This figure shows the co-authorship network connecting the top 25 collaborators of R. Axelrod. A scholar is included among the top collaborators of R. Axelrod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Axelrod. R. Axelrod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Vathiotis, Ioannis, Jennifer M. Johnson, Larry A. Harshyne, et al.. (2022). 672P Nivolumab (Nivo) and ipilimumab (Ipi) combined with radiotherapy (RT) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): Updated results on efficacy and correlative analysis. Annals of Oncology. 33. S850–S850.
2.
Curry, Joseph, Larry A. Harshyne, Alban J. Linnenbach, et al.. (2021). 861MO Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC). Annals of Oncology. 32. S787–S787.
3.
Zinner, Ralph, Jennifer M. Johnson, Madalina Tuluc, et al.. (2020). 968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer. Annals of Oncology. 31. S682–S682.
4.
Curry, Joseph, Larry A. Harshyne, Alban J. Linnenbach, et al.. (2020). 923P Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN). Annals of Oncology. 31. S665–S666.
5.
Manukian, Gregor, Jennifer M. Johnson, Adam Luginbuhl, et al.. (2020). Nivolumab and Ipilimumab Combined with Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: In-field Toxicity Analysis of a Phase I Clinical Trial. International Journal of Radiation Oncology*Biology*Physics. 108(3). S106–S107.
6.
Soest, Johan van, D.I. Rosenthal, R. Axelrod, et al.. (2017). A Feasibility Study on Incorporating Clinical Trial Quality Assurance Parameters into Outcome Prediction in Head and Neck Radiation Therapy Treatment. International Journal of Radiation Oncology*Biology*Physics. 99(2). E380–E380.
7.
Zhong, Hao, J. Wang, Johan van Soest, et al.. (2017). The Evidence Driven Dosimetric Constraints From Outcome Analysis of H&N Patients’ Data from NRG Oncology RTOG 0522 Trial. International Journal of Radiation Oncology*Biology*Physics. 99(2). S137–S137.
8.
Bar‐Ad, Voichita, Joshua D. Palmer, Yinzhi Lai, et al.. (2016). Neutrophil to lymphocyte ratio associated with prognosis of lung cancer. Clinical & Translational Oncology. 19(6). 711–717.
9.
Ad, Voichita Bar, Matthew E. Witek, Benjamin E. Leiby, et al.. (2012). Treatment-related Esophagitis for Patients With Locoregionally Advanced Non-small Cell Lung Cancer Treated With Involved-Field Radiation Therapy and Concurrent Chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 84(3). S551–S552.
10.
Ang, K. Kian, Richard H. Wheeler, David I. Rosenthal, et al.. (2010). A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): Impact of radiation and cisplatin intensity on outcome.. Journal of Clinical Oncology. 28(15_suppl). 5507–5507.
11.
Ang, K. Kian, Thomas F. Pajak, Ralph A. Wheeler, et al.. (2010). A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity. International Journal of Radiation Oncology*Biology*Physics. 77(1). 1–2.
12.
Ahn, Peter H., Mitchell Machtay, P.R. Anné, et al.. (2010). Results of a Phase I Trial of Induction Cisplatin, Docetaxel, 5-FU and Erlotinib followed by Cisplatin, Bevacizumab and Erlotinib with Radiotherapy for Advanced Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 78(3). S437–S437.
13.
Burtness, Barbara, Judith Manola, R. Axelrod, Athanassios Argiris, & Arlene A. Forastiere. (2008). A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals of Oncology. 19(5). 977–983.
14.
Mekhail, Tarek, Scott Gettinger, George R. Blumenschein, et al.. (2007). A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases. Journal of Clinical Oncology. 25(18_suppl). 7724–7724.
15.
Movsas, Benjamin, Jennifer Moughan, Corey J. Langer, et al.. (2007). Randomized trial of amifostine in locally advanced non-small cell lung cancer (NSCLC) patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of Radiation Therapy Oncology Group (RTOG) 9801. Journal of Clinical Oncology. 25(18_suppl). 7529–7529.
16.
Axelrod, R., Mitchell Machtay, P.R. Anné, et al.. (2005). Phase I study of weekly docetaxel (T), cisplatin (P) with daily celecoxib (C) and concurrent radiotherapy (RT) for patients with locally advanced head and neck cancer (HNC). Journal of Clinical Oncology. 23(16_suppl). 5598–5598.
17.
Argiris, Athanassios, et al.. (2005). Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): A phase II trial of the Eastern Cooperative Oncology Group (ECOG). Journal of Clinical Oncology. 23(16_suppl). 5528–5528.
18.
Bellet, Robert E., Daniel P. Petrylak, Basil Kasimis, et al.. (2004). Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4657–4657.
19.
Axelrod, R., et al.. (1998). Clinical Process Improvement As a Means of Facilitating Health Care System Integration. The Joint Commission Journal on Quality Improvement. 24(3). 143–153.
20.
Axelrod, R. & Kathleen S. Lowney. (1993). Elective introduction to oncology. Journal of Cancer Education. 8(1). 31–34.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Lora S. Wang Breakdown of academic impact, for papers by Tsien Fua Breakdown of academic impact, for papers by Sophia Hsu Breakdown of academic impact, for papers by Manuel Molina Breakdown of academic impact, for papers by Alistair Robertson Breakdown of academic impact, for papers by Virginia Osborn Breakdown of academic impact, for papers by Gopal Bajaj Breakdown of academic impact, for papers by Everett E. Vokes Breakdown of academic impact, for papers by Bhavana V. Chapman Breakdown of academic impact, for papers by Ashwini Budrukkar